Heng Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Heng Luo has a total of 388 co-authors. Here are the top co-authors by number of shared publications:
Jia Yu
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, China
44 shared publicationsSha Cheng
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, China
34 shared publications- Bixue Xu
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang 550014, China
23 shared publications Gang Yu
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang 550014, China; Natural Products Research Center of Guizhou Province, Guizhou Medical University, Guiyang 550014, China
15 shared publications- Jia Yu
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang 550014, China
10 shared publications Mashaal Ahmad
Of Medicinal Plants State Key Laboratory for Functionsand Applications Guizhou Medical University 550014 Guiyang China
10 shared publications
Latest Publications
- Open Access
Small-Leaved Kuding Tea Extract Fractions Attenuate Hyperlipidemia and Hepatic Steatosis in Mice: Association with Upregulation of Fatty Acid β-Oxidation Enzymes and Improvement of Metabolic Biomarkers
Background/Objectives: Hyperlipidemia is a prevalent metabolic disorder that increases cardiovascular disease risk and is associated with lipid accumulation, inflammation, and oxidative stress. Small-leaved Kuding tea (SLKT) has multiple health benefits, but its lipid-lowering mechanisms remain unclear. This study evaluated the therapeutic effects of different SLKT fractions on hyperlipidemia and investigated their modulation of the fatty acid degradation pathway. Methods: A hyperlipidemia mouse model was established using a high-fat diet for 8 weeks. Sixty successfully modeled mice were randomly divided into six groups: model control, anhydrous ethanol fraction (SLK-AE), ethyl acetate fraction (SLK-EA), n-butanol fraction (SLK-NA), water-soluble fraction (SLK-WA), and simvastatin (positive control). Mice received daily gavage for 8 weeks. Serum biochemical indices, inflammatory factors, hepatic oxidative stress markers, and liver histopathology were assessed. Protein expression levels of ACADM, EHHADH, and HADHB in the liver were detected by Western blot. Results: SLKT fractions significantly reduced body weight, fat mass, serum TC, TG, LDL-C, Glu, NEFA, ALT, AST, TNF-α, IL-1β, IL-6, and LPS, while increasing HDL-C (p < 0.05). Hepatic TC, TG, ALT, AST, and MDA decreased, and SOD increased (p < 0.05). Histological staining revealed markedly reduced lipid droplets in hepatocytes. Furthermore, SLKT significantly upregulated hepatic protein expression of ACADM, EHHADH, and HADHB, key enzymes in fatty acid β-oxidation (p < 0.05). Conclusions: SLKT effectively ameliorates hyperlipidemia by improving lipid profiles, reducing serum biomarkers of liver injury and pro-inflammatory cytokines, and upregulating key fatty acid degradation enzymes. These findings support SLKT as a potential natural therapeutic agent for hyperlipidemia and associated metabolic disorders.
Open AccessSmall-Leaved Kuding Tea Extract Fractions Attenuate Hyperlipidemia and Hepatic Steatosis in Mice: Association with Upregulation of Fatty Acid β-Oxidation Enzymes and Improvement of Metabolic Biomarkers
Background/Objectives: Hyperlipidemia is a prevalent metabolic disorder that increases cardiovascular disease risk and is associated with lipid accumulation, inflammation, and oxidative stress. Small-leaved Kuding tea (SLKT) has multiple health benefits, but its lipid-lowering mechanisms remain unclear. This study evaluated the therapeutic effects of different SLKT fractions on hyperlipidemia and investigated their modulation of the fatty acid degradation pathway. Methods: A hyperlipidemia mouse model was established using a high-fat diet for 8 weeks. Sixty successfully modeled mice were randomly divided into six groups: model control, anhydrous ethanol fraction (SLK-AE), ethyl acetate fraction (SLK-EA), n-butanol fraction (SLK-NA), water-soluble fraction (SLK-WA), and simvastatin (positive control). Mice received daily gavage for 8 weeks. Serum biochemical indices, inflammatory factors, hepatic oxidative stress markers, and liver histopathology were assessed. Protein expression levels of ACADM, EHHADH, and HADHB in the liver were detected by Western blot. Results: SLKT fractions significantly reduced body weight, fat mass, serum TC, TG, LDL-C, Glu, NEFA, ALT, AST, TNF-α, IL-1β, IL-6, and LPS, while increasing HDL-C (p < 0.05). Hepatic TC, TG, ALT, AST, and MDA decreased, and SOD increased (p < 0.05). Histological staining revealed markedly reduced lipid droplets in hepatocytes. Furthermore, SLKT significantly upregulated hepatic protein expression of ACADM, EHHADH, and HADHB, key enzymes in fatty acid β-oxidation (p < 0.05). Conclusions: SLKT effectively ameliorates hyperlipidemia by improving lipid profiles, reducing serum biomarkers of liver injury and pro-inflammatory cytokines, and upregulating key fatty acid degradation enzymes. These findings support SLKT as a potential natural therapeutic agent for hyperlipidemia and associated metabolic disorders.
- 19 September 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43 (10) , 291
Gastrodin enhances the spleen immune function in erythroleukemia by regulating T-cell receptor signaling pathway
Erythroleukemia is a malignant hematological disorder often accompanied by severe immunosuppression, with T cell dysfunction playing a central role. Gastrodin, which is derived from Gastrodia elata, has been proven to possess various pharmacological activities such as neuroprotection and immunomodulation. However, whether it can effectively improve the immune function in erythroleukemia has not been reported. Our results demonstrated that gastrodin treatment significantly alleviated splenomegaly and inhibited the malignant progression in erythroleukemia mice. Moreover, it markedly enhanced the proliferative capacity of splenic T cells and promoted the secretion of immune - related cytokines. Mechanistically, gastrodin upregulated the expression of key molecules in the T cell receptor signaling pathway, including LCK, ZAP-70, ITK, PKC, IKK, and NFκB, at both the mRNA and protein phosphorylation levels. Notably, through integrated bioinformatics analysis, molecular docking, and cellular thermal shift assays, we found that gastrodin exhibits moderate interaction with the transcription factor Fli-1 in erythroleukemia. Collectively, this study provides the first evidence that gastrodin enhances splenic immune function in erythroleukemia by modulating the T cell receptor (TCR) signaling pathway. Cellular thermal shift assay identified Fli-1 as a protein capable of physically interacting with gastrodin, although its functional contribution remains to be further explored. These findings highlight gastrodin as a promising immunotherapeutic candidate for erythroleukemia.
- 19 September 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43 (10) , 291
Gastrodin enhances the spleen immune function in erythroleukemia by regulating T-cell receptor signaling pathway
Erythroleukemia is a malignant hematological disorder often accompanied by severe immunosuppression, with T cell dysfunction playing a central role. Gastrodin, which is derived from Gastrodia elata, has been proven to possess various pharmacological activities such as neuroprotection and immunomodulation. However, whether it can effectively improve the immune function in erythroleukemia has not been reported. Our results demonstrated that gastrodin treatment significantly alleviated splenomegaly and inhibited the malignant progression in erythroleukemia mice. Moreover, it markedly enhanced the proliferative capacity of splenic T cells and promoted the secretion of immune - related cytokines. Mechanistically, gastrodin upregulated the expression of key molecules in the T cell receptor signaling pathway, including LCK, ZAP-70, ITK, PKC, IKK, and NFκB, at both the mRNA and protein phosphorylation levels. Notably, through integrated bioinformatics analysis, molecular docking, and cellular thermal shift assays, we found that gastrodin exhibits moderate interaction with the transcription factor Fli-1 in erythroleukemia. Collectively, this study provides the first evidence that gastrodin enhances splenic immune function in erythroleukemia by modulating the T cell receptor (TCR) signaling pathway. Cellular thermal shift assay identified Fli-1 as a protein capable of physically interacting with gastrodin, although its functional contribution remains to be further explored. These findings highlight gastrodin as a promising immunotherapeutic candidate for erythroleukemia.
- Open Access
- 21 August 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1786264
Dendrobium officinale polysaccharide ameliorates polycystic ovary syndrome by modulating the MAPK/ERK signaling pathway
Introduction: Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders affecting women of reproductive age. Dendrobium officinale polysaccharides (DOP) have shown multiple pharmacological activities, but their therapeutic effects and underlying mechanisms in PCOS remain incompletely understood. Methods: A dehydroepiandrosterone (DHEA)-induced mouse model of PCOS was established to evaluate the effects of DOP. Estrous cyclicity, ovarian histopathology, serum hormone levels, RT-qPCR, and Western blot analyses were performed to assess reproductive function, endocrine changes, and MAPK/ERK-related signaling. Results: DOP treatment restored estrous cyclicity, improved ovarian morphology, and partially normalized serum luteinizing hormone, follicle-stimulating hormone, and testosterone levels. In addition, DOP reduced ERK1/2 phosphorylation and downregulated the expression of CYP17A1 and CYP19A1. Conclusion: DOP ameliorated reproductive and endocrine abnormalities in a DHEA-induced mouse model of PCOS. The findings suggest that modulation of MAPK/ERK signaling may contribute to the biological effects of DOP, although further mechanistic studies are required to establish causal relationships.
- 21 August 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1786264
Open AccessDendrobium officinale polysaccharide ameliorates polycystic ovary syndrome by modulating the MAPK/ERK signaling pathway
Introduction: Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders affecting women of reproductive age. Dendrobium officinale polysaccharides (DOP) have shown multiple pharmacological activities, but their therapeutic effects and underlying mechanisms in PCOS remain incompletely understood. Methods: A dehydroepiandrosterone (DHEA)-induced mouse model of PCOS was established to evaluate the effects of DOP. Estrous cyclicity, ovarian histopathology, serum hormone levels, RT-qPCR, and Western blot analyses were performed to assess reproductive function, endocrine changes, and MAPK/ERK-related signaling. Results: DOP treatment restored estrous cyclicity, improved ovarian morphology, and partially normalized serum luteinizing hormone, follicle-stimulating hormone, and testosterone levels. In addition, DOP reduced ERK1/2 phosphorylation and downregulated the expression of CYP17A1 and CYP19A1. Conclusion: DOP ameliorated reproductive and endocrine abnormalities in a DHEA-induced mouse model of PCOS. The findings suggest that modulation of MAPK/ERK signaling may contribute to the biological effects of DOP, although further mechanistic studies are required to establish causal relationships.
- 20 June 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 251, 118181
BLM as a potential therapeutic target in cutaneous malignant melanoma
- 20 June 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 251, 118181
BLM as a potential therapeutic target in cutaneous malignant melanoma
- 5 June 2026
- Published by Elsevier in Ceramics International
- Vol. 52 (19) , 35004-35014
Co2+-doped GDY-QDs/Gd2O3 nanocomposites with enhanced magnetic properties, preserved fluorescence and improved biocompatibility
- 5 June 2026
- Published by Elsevier in Ceramics International
- Vol. 52 (19) , 35004-35014
Co2+-doped GDY-QDs/Gd2O3 nanocomposites with enhanced magnetic properties, preserved fluorescence and improved biocompatibility
- 28 May 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 180, 110032
Structure-optimized 4-trifluoromethylquinoline derivatives: Dual enhancement of SGK1 inhibition and anti-prostate cancer efficacy
- 28 May 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 180, 110032
Structure-optimized 4-trifluoromethylquinoline derivatives: Dual enhancement of SGK1 inhibition and anti-prostate cancer efficacy
- Open Access
- 30 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 711
Neuroprotective Effects of Rosa roxburghii Tratt Juice Concentrate Powder in Parkinson’s Disease Mice via the PI3K/AKT Signaling Pathway
Background: The absence of disease-modifying treatments for Parkinson’s disease (PD)—a neurodegenerative condition with escalating global incidence—represents a critical unmet medical need. Traditionally utilized for both dietary consumption and medicinal preparations, the fruit derived from Rosa roxburghii Tratt demonstrates a remarkably rich profile of biologically active compounds, with flavonoids, triterpenoids, and organic acids representing the predominant classes. Experimental evidence indicates that these compounds elicit robust antioxidative, anti-inflammatory, and neuroprotective effects, making them promising candidates for neurodegenerative disease modulation. This study aimed to systematically evaluate the neuroprotective effects of Rosa roxburghii Tratt juice concentrate powder (RRJCP) across the preventive, interventional, and therapeutic stages of PD and to elucidate its underlying molecular mechanisms. Methods: Rosa roxburghii Tratt juice was subjected to rotary evaporation concentration and vacuum freeze-drying to obtain the juice concentrate powder. C57BL/6 mice were randomly assigned to three main groups (prevention, intervention, and treatment), each containing subgroups including a normal control, an MPTP model group, low-, medium-, and high-dose RRCJP groups (50, 100, and 200 mg/kg), and a positive control Madopar group, totaling 18 subgroups. A chronic MPTP-induced PD mouse model was established. Motor function was assessed via the open field test, pole test, and wire hang test. Substantia nigra neuronal morphology was examined by hematoxylin and eosin staining. The area of tyrosine hydroxylase (TH)-positive regions was measured by immunohistochemistry. The levels of oxidative stress indicators in serum were measured using biochemical kits. Network pharmacology was employed to predict core targets, and the expression of PI3K/AKT pathway and apoptosis-related proteins was determined by Western blotting. Results: Compared with the MPTP model group, RRCJP (200 mg/kg) significantly increased the total distance traveled in the open field, shortened the pole climbing time, and improved the wire hang score. It attenuated the morphological disorganization and nuclear pyknosis of substantia nigra neurons, increased the TH-positive area and TH protein expression, reduced serum MDA content, and elevated the activities of SOD and GSH-Px. Network pharmacology analysis indicated that the PI3K/AKT signaling pathway was among the core targets. Western blotting results further showed that the juice concentrate powder upregulated the expression of p-PI3K, p-AKT, and Bcl-2, while downregulating Bax and Cleaved Caspase-3 levels, which was consistent with the network pharmacology prediction. Conclusions: RRCJP exerts neuroprotective effects across the preventive, interventional, and therapeutic stages in PD model mice, the mechanisms of which may be associated with activation of the PI3K/AKT signaling pathway, attenuation of oxidative stress, and inhibition of neuronal apoptosis.
- 30 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 711
Open AccessNeuroprotective Effects of Rosa roxburghii Tratt Juice Concentrate Powder in Parkinson’s Disease Mice via the PI3K/AKT Signaling Pathway
Background: The absence of disease-modifying treatments for Parkinson’s disease (PD)—a neurodegenerative condition with escalating global incidence—represents a critical unmet medical need. Traditionally utilized for both dietary consumption and medicinal preparations, the fruit derived from Rosa roxburghii Tratt demonstrates a remarkably rich profile of biologically active compounds, with flavonoids, triterpenoids, and organic acids representing the predominant classes. Experimental evidence indicates that these compounds elicit robust antioxidative, anti-inflammatory, and neuroprotective effects, making them promising candidates for neurodegenerative disease modulation. This study aimed to systematically evaluate the neuroprotective effects of Rosa roxburghii Tratt juice concentrate powder (RRJCP) across the preventive, interventional, and therapeutic stages of PD and to elucidate its underlying molecular mechanisms. Methods: Rosa roxburghii Tratt juice was subjected to rotary evaporation concentration and vacuum freeze-drying to obtain the juice concentrate powder. C57BL/6 mice were randomly assigned to three main groups (prevention, intervention, and treatment), each containing subgroups including a normal control, an MPTP model group, low-, medium-, and high-dose RRCJP groups (50, 100, and 200 mg/kg), and a positive control Madopar group, totaling 18 subgroups. A chronic MPTP-induced PD mouse model was established. Motor function was assessed via the open field test, pole test, and wire hang test. Substantia nigra neuronal morphology was examined by hematoxylin and eosin staining. The area of tyrosine hydroxylase (TH)-positive regions was measured by immunohistochemistry. The levels of oxidative stress indicators in serum were measured using biochemical kits. Network pharmacology was employed to predict core targets, and the expression of PI3K/AKT pathway and apoptosis-related proteins was determined by Western blotting. Results: Compared with the MPTP model group, RRCJP (200 mg/kg) significantly increased the total distance traveled in the open field, shortened the pole climbing time, and improved the wire hang score. It attenuated the morphological disorganization and nuclear pyknosis of substantia nigra neurons, increased the TH-positive area and TH protein expression, reduced serum MDA content, and elevated the activities of SOD and GSH-Px. Network pharmacology analysis indicated that the PI3K/AKT signaling pathway was among the core targets. Western blotting results further showed that the juice concentrate powder upregulated the expression of p-PI3K, p-AKT, and Bcl-2, while downregulating Bax and Cleaved Caspase-3 levels, which was consistent with the network pharmacology prediction. Conclusions: RRCJP exerts neuroprotective effects across the preventive, interventional, and therapeutic stages in PD model mice, the mechanisms of which may be associated with activation of the PI3K/AKT signaling pathway, attenuation of oxidative stress, and inhibition of neuronal apoptosis.
- Open Access
- 27 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 682
Zhuangyang Bushen Pill Attenuates Renal Injury in Chronic Glomerulonephritis by Suppressing the MAPK Signaling Pathway
Background/Objectives: Chronic glomerulonephritis (CGN) is a progressive chronic kidney disease that can ultimately advance to end-stage renal disease (ESRD). Zhuangyang Bushen Pill (ZYBSW) is a traditional Chinese herbal formulation derived from the Yi ethnic medicine of Yunnan Province, and it has been widely employed in folk practice for the amelioration of chronic nephritis and renal dysfunction. This study was designed to evaluate the therapeutic efficacy of ZYBSW against CGN and to provide preliminary insights into its underlying mechanisms of action. Methods: The nephropathy model was induced in mice by tail vein injection of ADR (10 mg/kg). Renal function was evaluated by measuring relevant biochemical parameters, and renal histopathological alterations were examined using HE staining. Chemical constituents of ZYBSW were analyzed by LC-MS/MS. Its mechanisms of action were investigated using network pharmacology, WGCNA, molecular docking, multiplex immunofluorescence, and Western blotting. Results: ZYBSW significantly reduced ACR by 88.9%, SCr by 56.4%, and BUN by 30.4%, increased ALB by 32.4%, and alleviated renal histopathological damage (all p < 0.01). LC-MS/MS analysis identified 419 chemical constituents in ZYBSW. Network pharmacology, WGCNA, and molecular docking experiments identified EGFR and DUSP1 as potential targets, and indicated the MAPK pathway as a key pathway. Mechanistic studies revealed that ZYBSW significantly inhibited EGFR expression in renal tissue, enhanced DUSP1 expression, and reduced the phosphorylation levels of ERK, JNK, and p38. Conclusions: This study reveals ZYBSW can effectively alleviate CGN, with EGFR and DUSP1 as likely therapeutic targets, and its mechanism of action primarily involves regulating the MAPK signaling pathway.
- 27 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (5) , 682
Open AccessZhuangyang Bushen Pill Attenuates Renal Injury in Chronic Glomerulonephritis by Suppressing the MAPK Signaling Pathway
Background/Objectives: Chronic glomerulonephritis (CGN) is a progressive chronic kidney disease that can ultimately advance to end-stage renal disease (ESRD). Zhuangyang Bushen Pill (ZYBSW) is a traditional Chinese herbal formulation derived from the Yi ethnic medicine of Yunnan Province, and it has been widely employed in folk practice for the amelioration of chronic nephritis and renal dysfunction. This study was designed to evaluate the therapeutic efficacy of ZYBSW against CGN and to provide preliminary insights into its underlying mechanisms of action. Methods: The nephropathy model was induced in mice by tail vein injection of ADR (10 mg/kg). Renal function was evaluated by measuring relevant biochemical parameters, and renal histopathological alterations were examined using HE staining. Chemical constituents of ZYBSW were analyzed by LC-MS/MS. Its mechanisms of action were investigated using network pharmacology, WGCNA, molecular docking, multiplex immunofluorescence, and Western blotting. Results: ZYBSW significantly reduced ACR by 88.9%, SCr by 56.4%, and BUN by 30.4%, increased ALB by 32.4%, and alleviated renal histopathological damage (all p < 0.01). LC-MS/MS analysis identified 419 chemical constituents in ZYBSW. Network pharmacology, WGCNA, and molecular docking experiments identified EGFR and DUSP1 as potential targets, and indicated the MAPK pathway as a key pathway. Mechanistic studies revealed that ZYBSW significantly inhibited EGFR expression in renal tissue, enhanced DUSP1 expression, and reduced the phosphorylation levels of ERK, JNK, and p38. Conclusions: This study reveals ZYBSW can effectively alleviate CGN, with EGFR and DUSP1 as likely therapeutic targets, and its mechanism of action primarily involves regulating the MAPK signaling pathway.
- Open Access
- 27 April 2026
- Published by Spandidos Publications in Oncology Letters
- Vol. 31 (6) , 1-15
Exploring the mechanism of action of glaucocalyxin D against acute myeloid leukemia using network pharmacology, molecular docking and cellular experiments
Glaucocalyxin D (GLD), an ent‑kaurane diterpenoid isolated from Isodon species, exhibits extensive pharmacological potential; however, its mechanism of action against acute myeloid leukemia (AML) remains to be elucidated. The present study employed a combined network pharmacology and experimental approach to elucidate the anti‑AML mechanisms of GLD. Potential targets were identified using database mining and a protein‑protein interaction network was constructed. The Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes enrichment analyses highlighted the JAK‑STAT signaling pathway as central to action by GLD. Molecular docking predicted stable binding of GLD to core targets, including STAT3. Experimental validation in HEL and K562 AML cells demonstrated that GLD potently and dose‑dependently inhibits cell proliferation, with efficacy similar to the standard chemotherapeutic agent doxorubicin. Mechanistically, GLD suppressed the phosphorylation of JAK2 and STAT3. GLD also induced mitochondrial apoptosis by modulating the Bcl‑2/Bax ratio and triggered G2/M phase arrest by downregulating cyclin B1 and CDK1. These findings delineated a coherent mechanism whereby GLD exerts anti‑leukemic effects by inhibiting the JAK‑STAT pathway, supporting its potential as a novel lead compound for AML therapy in the future.
- 27 April 2026
- Published by Spandidos Publications in Oncology Letters
- Vol. 31 (6) , 1-15
Open AccessExploring the mechanism of action of glaucocalyxin D against acute myeloid leukemia using network pharmacology, molecular docking and cellular experiments
Glaucocalyxin D (GLD), an ent‑kaurane diterpenoid isolated from Isodon species, exhibits extensive pharmacological potential; however, its mechanism of action against acute myeloid leukemia (AML) remains to be elucidated. The present study employed a combined network pharmacology and experimental approach to elucidate the anti‑AML mechanisms of GLD. Potential targets were identified using database mining and a protein‑protein interaction network was constructed. The Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes enrichment analyses highlighted the JAK‑STAT signaling pathway as central to action by GLD. Molecular docking predicted stable binding of GLD to core targets, including STAT3. Experimental validation in HEL and K562 AML cells demonstrated that GLD potently and dose‑dependently inhibits cell proliferation, with efficacy similar to the standard chemotherapeutic agent doxorubicin. Mechanistically, GLD suppressed the phosphorylation of JAK2 and STAT3. GLD also induced mitochondrial apoptosis by modulating the Bcl‑2/Bax ratio and triggered G2/M phase arrest by downregulating cyclin B1 and CDK1. These findings delineated a coherent mechanism whereby GLD exerts anti‑leukemic effects by inhibiting the JAK‑STAT pathway, supporting its potential as a novel lead compound for AML therapy in the future.
- Open Access
Pyroptosis in endometritis: Molecular mechanisms, pathogenic roles, and therapeutic opportunities